Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation

Circulation

Volumn 113, Issue 4, 2006, Pages 544-554

  Wang, Jianxun ^a   Song, Ye ^a   Elsherif, Laila ^a   Song, Zhenyuan ^a   Zhou, Guihua ^a   Prabhu, Sumanth D ^a   Saari, Jack T ^b   Cai, Lu ^a  

^a University of Louisville School of Medicine   (United States)

^b GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Cardiomyopathy; Diabetes mellitus; Myocardium; Nutrition; Prevention

Indexed keywords

CADMIUM; FATTY ACID; GLUCOSE; METALLOTHIONEIN; PALMITIC ACID; SMALL INTERFERING RNA; ZINC SULFATE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG PROTEIN BINDING; EXPOSURE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; STREPTOZOCIN DIABETES; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HEART MUSCLE; HEART MUSCLE CELL; METABOLISM;

ANIMALS; CADMIUM; CARDIOMYOPATHIES; CELL SURVIVAL; CELLS, CULTURED; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, NONESTERIFIED; GLUCOSE; MALE; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; RNA, MESSENGER; RNA, SMALL INTERFERING; ZINC SULFATE;

EID: 33644862200     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.537894     Document Type: Article

References (50)

1. Trost S, LeWinter M. Diabetic cardiomyopathy. Curr Treat Options Cardiovasc Med. 2001;3:481-492.
2. Giles TD. The patient with diabetes mellitus and heart failure: at-risk issues. Am J Med. 2003;115(suppl 8A):107S-110S.
3. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938-1948.
4. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy. Cardiovasc Toxicol. 2001;1:181-193.
5. Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab. 2003;29:579-585.
6. Vega-Lopez S, Devaraj S, Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Invest Med. 2004;52:24-32.
7. Kang YJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med. 1999;222:263-273.
8. Cai L. Metallothionein as an adaptive protein prevents diabetes and its toxicity. Nonlinearity in Biol-Toxicol-Med. 2004;2:89-103.
9. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorabicin cardiotoxicity. J Clin Invest. 1997;100:1501-1506.
10. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem. 2000;275:13690-13698.
11. Kang YJ, Zhou ZX, Wu H, Wang GW, Saari JT, Klein JB. Metallothionein inhibits myocardial apoptosis in copper-deficient mice: role of atrial natriuretic peptide. Lab Invest. 2000;80:745-757.
12. Cai L, Li Y, Wang L, Kang YJ. Suppression by metallothionein of early-phase myocardial cell death prevents the late development of diabetic cardiomyopathy. Diabetes 2003;52(suppl 1):172.
13. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, Kang YJ. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005;54:1829-1837.
14. Song Y, Wang J, Li Y, Du Y, Arteel GE, Saari JT, Kang YJ, Cai L. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol. 2005;167:17-26.
15. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 2002;51:174-181.
16. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes. 2003;52:777-783.
17. Ali MM, Frei E, Straub J, Breuer A, Wiessler M. Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Toxicology. 2002;179:85-93.
18. Satoh M, Naganuma A, Imura N. Modulation of Adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci. 2000;67:627-634.
19. Mulder TP, van der Sluys Veer A, Verspaget HW, Griffioen G, Pena AS, Janssens AR, Lamers CB. Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 1994;9:472-477.
20. Sturniolo GC, Mestriner C, Irato P, Albergoni V, Longo G, D'Inca R. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol. 1999;94:334-338.
21. Chvapil M, Owen JA. Effect of zinc on acute and chronic isoproterenol induced heart injury. J Mol Cell Cardiol. 1977;9:151-159.
22. Li Y, Gu Y, Song Y, Zhang L, Kang YJ, Prabhu SD, Cai L. Cardiac functional analysis by electrocardiography, echocardiography and in situ hemodynamics in streptozotocin-induced diabetic mice. J Health Sci. 2004;50:356-365.
23. Elsherif L, Wang L, Saari JT, Kang YJ. Regression of dietary copper restriction-induced cardiomyopathy by copper repletion in mice. J Nutr. 2004;134:855-860.
24. Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of Adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. 1979;63:1877-1883.
25. Sun X, Zhou Z, Kang YJ. Attenuation of doxorabicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 2001;61:3382-3387.
26. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol. 2004;165:2033-2043.
27. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes. 2002;51:2709-2718.
28. Stehbens WE. Oxidative stress, toxic hepatitis, and antioxidants with particular emphasis on zinc. Exp Mol Pathol. 2003;75:265-276.
29. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem. 2000;275:38957-38960.
30. Faure P, Benhamou PY, Perard A, Halimi S, Roussel AM. Lipid peroxidation in insulin-dependent diabetic patients with early retina degenerative lesions: effects of an oral zinc supplementation. Eur J Clin Nutr. 1995;49:282-288.
31. Kajanachumpol S, Srisurapanon S, Supanit I, Roongpisuthipong C, Apibal S. Effect of zinc supplementation on zinc status, copper status and cellular immunity in elderly patients with diabetes mellitus. J Med Assoc Thai. 1995;78:344-349.
32. Gupta R, Garg VK, Mathur DK, Goyal RK. Oral zinc therapy in diabetic neuropathy. J Assoc Phys India. 1998;46:939-942.
33. Uchiyama S, Yamaguchi M. Alteration in serum and bone component findings induced in streptozotocin-diabetic rats is restored by zinc acexamate. Int J Mol Med. 2003;12:949-954.
34. Monkemann H, De Vriese AS, Blom HJ, Kluijtmans LA, Heil SG, Schild HH, Golubnitschaja O. Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids. 2002;23:331-336.
35. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol. 2003;3:219-228.
36. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest. 2000;80:513-527.
37. Cai L, Cherian MG. Adaptive response to ionizing radiation-induced chromosome aberrations in rabbit lymphocytes: effect of pre-exposure to zinc, and copper salts. Mutat Res. 1996;369:233-241.
38. Cai L, Cherian MG, Iskander S, Leblanc M, Hammond RR. Metallothionein induction in human CNS in vitro: neuroprotection from ionizing radiation. Int J Radiat Biol. 2000;76:1009-1017.
39. Cai L, Iskander S, Cherian MG, Hammond RR. Zinc- or cadmium-pre-induced metallothionein protects human central nervous system cells and astrocytes from radiation-induced apoptosis. Toxicol Lett. 2004;146: 217-226.
40. Tang X, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-L1 fibroblasts and adipocytes. J Nutr. 2001;131:1414-1420.
41. Miranda ER, Dey CS. Effect of chromium and zinc on insulin signaling in skeletal muscle cells. Biol Trace Elem Res. 2004;101:19-36.
42. Brandao-Neto J, Silva CA, Figueiredo NB, Shuhama T, Holanda MB, Diniz JM. Zinc kinetics in insulin-dependent diabetes mellitus patients. Biometals. 2000;13:141-145.
43. Kinlaw WB, Levine AS, Morley JE, Silvis SE, McClain CJ. Abnormal zinc metabolism in type II diabetes mellitus. Am J Med. 1983;75:273-277.
44. Salgueiro MJ, Krebs N, Zubillaga MB, Weill R, Postaire E, Lysionek AE, Caro RA, De Paoli T, Hager A, Boccio J. Zinc and diabetes mellitus: is there a need of zinc supplementation in diabetes mellitus patients? Biol Trace Elem Res. 2001;81:215-228.
45. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817-826.
46. Maret W The function of zinc metallothionein: a link between cellular zinc and redox state. J Nutr. 2000;130(suppl 5S):1455S-1458S.
47. Igic PG, Lee E, Harper W, Roach KW. Toxic effects associated with consumption of zinc. Mayo Clin Proc. 2002;77:713-716.
48. Hein MS. Copper deficiency anemia and nephrosis in zinc-toxicity: a case report. S D J Med. 2003;56:143-147.
49. Irving JA, Mattman A, Lockitch G, Farrell K, Wadsworth LD. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ. 2003;169:129-131.
50. Bonham M, O'Connor JM, McAnena LB, Walsh PM, Downes CS, Hannigan BM, Strain JJ. Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men. Biol Trace Elem Res. 2003;93:75-86.